News
The tussle had centred on the development of mRNA jab technology, which was at the forefront of the fight against Covid-19.
1d
TipRanks on MSNGSK’s New Study on GSK5764227: A Potential Game-Changer in Gastrointestinal Cancer TreatmentGlaxoSmithKline plc (UK) (($GB:GSK)) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) is ...
GlaxoSmithKline Pharmaceuticals reports a 12% increase in net profit to Rs 279 crore for the June quarter despite a slight ...
Indian drugmaker GlaxoSmithKline Pharma reported its first quarterly revenue decline in more than two years on Friday, ...
Delhi Police have busted a medicine racket making counterfeit life-saving drugs using the names of big pharma companies such ...
GlaxoSmithKline said it would buy cancer-focused drug company Tesaro for about $4.16 billion, positioning the health-care giant in a promising, but fiercely competitive, area of medicine.
The Cambridge site of an international biotechnology company will cease manufacturing, leaving 150 people without a job.
Less than two months after GlaxoSmithKline pledged to cap out-of-pocket costs for its inhalers at $35 a month, Sen. Maggie Hassan (D-N.H.) is accusing the company of circumventing that vow through ...
GlaxoSmithKline PLC GSK 0.79% has reported positive results from a study of a cancer drug in a clinical trial that a senior figure in the company said justified the decision to acquire cancer ...
GlaxoSmithKline LLC will pay $3 billion and plead guilty to promoting two popular drugs for unapproved uses and to failing to disclose important safety information on a third in the largest heal ...
GlaxoSmithKline (GSK-0.81%) has confirmed plans to separate its consumer and pharmaceutical business units. However, an activist investor appears to want the big drugmaker to take more drastic ...
As I looked into the story at the time, several things became clear: GlaxoSmithKline was promoting the drug for use by teenagers even though it had never been cleared by the FDA for anyone under ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results